Silberer H, Kuppers B, Mickisch O, Baniewicz W, Drescher M, Traber L, Kempf A, Schmidt-Gayk H. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome. Clin Lab. 2005;51(3-4):117-26.

Saibeni S, Cortinovis I, Beretta L, Tatarella M, Ferraris L, Rondonotti E, Corbellini A, Bortoli A, Colombo E, Alvisi C, Imperiali G, de Franchis R; Gruppo di Studio per le Malattie Infiammatorie Intestinali. Gender and disease activity influence health-related quality of life in inflammatory bowel diseases. Hepatogastroenterology. 2005 Mar-Apr;52(62):509-15.

Khorrami Mashhadi S, Trapero M, Gisbert JP, Gomez Dominguez E, Mate Jimenez J. A pilot study on the endoscopic surveillance of colorectal dysplasia and cancer in long-standing ulcerative colitis. Rev Esp Enferm Dig. 2005 Jan;97(1):16-23.

Zhang H, Ouyang Q, Wen ZH, Fiocchi C, Liu WP, Chen DY, Li FY. Significance of glucocorticoid receptor expression in colonic mucosal cells of patients with ulcerative colitis. World J Gastroenterol. 2005 Mar 28;11(12):1775-8.

Hauser W, Janke KH, Stallmach A. Mental Disorder and Psychologic Distress in Patients With Ulcerative Colitis After Ileal Pouch-Anal Anastomosis. Dis Colon Rectum. 2005 Mar 22;  

Lee GH, Kim CG, Kim JS, Jung HC, Song IS.  [Frequency analysis of NOD2 gene mutations in Korean patients with Crohn's disease] Korean J Gastroenterol. 2005 Mar;45(3):162-8.

Actis GC, Ottobrelli A, Baldi S, Scappaticci E, Modena V, Fusaro E, Mengozzi G, Rizzetto M. Mesalamine-induced lung injury in a patient with ulcerative colitis and a confounding autoimmune background: a case report. Mt Sinai J Med. 2005 Mar;72(2):136-40.

Hanabata N, Sasaki Y, Tanaka M, Tsuji T, Hatada Y, Hada R, Munakata A. Vascular endothelial growth factor expression and microvessel parameters of colonic mucosa correlate with sensitivity to steroid in patients with ulcerative colitis. Scand J Gastroenterol. 2005 Feb;40(2):188-93.

Sipos F, Molnar B, Zagoni T, Berczi L, Tulassay Z. Growth in Epithelial Cell Proliferation and Apoptosis Correlates Specifically to the Inflammation Activity of Inflammatory Bowel Diseases: Ulcerative Colitis Shows Specific p53- and EGFR Expression Alterations. Dis Colon Rectum. 2005 Feb 23;

Azzolini F, Pagnini C, Camellini L, Scarcelli A, Merighi A, Primerano AM, Bertani A, Antonioli A, Manenti F, Rigo GP. Proposal of a new clinical index predictive of endoscopic severity in ulcerative colitis. Dig Dis Sci. 2005 Feb;50(2):246-51.

Itzkowitz SH, Present DH; Crohn's and Colitis Foundation of America Colon Cancer in IBD Study Group. Consensus conference: Colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis. 2005 Mar;11(3):314-21.

Langhorst J, Anthonisen IB, Steder-Neukamm U, Ludtke R, Spahn G, Michalsen A, Dobos GJ. Amount of systemic steroid medication is a strong predictor for the use of complementary and alternative medicine in patients with inflammatory bowel disease: results from a German national survey. Inflamm Bowel Dis. 2005 Mar;11(3):287-95.

Janke KH, Klump B, Gregor M, Meisner C, Haeuser W. Determinants of life satisfaction in inflammatory bowel disease. Inflamm Bowel Dis. 2005 Mar;11(3):272-86.

Frieri G, Pimpo M, Galletti B, Palumbo G, Corrao G, Latella G, Chiaramonte M, Caprilli R. Long-term oral plus topical mesalazine in frequently relapsing ulcerative colitis. Dig Liver Dis. 2005 Feb;37(2):92-6. 

Kim KJ, Myung SJ, Hong SS, Lee YJ, Lee SM, Byeon JS, Yang SK, Hong WS, Kim JH, Min YI. Clinical usefulness of glucocorticoid receptor beta expression and NF-kappaB activity in patients with ulcerative colitis Korean J Gastroenterol. 2005 Feb;45(2):103-10.

Costa F, Mumolo MG, Ceccarelli L, Bellini M, Romano MR, Sterpi C, Ricchiuti A, Marchi S, Bottai M. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut. 2005 Mar;54(3):364-8.

Sartor RB. Probiotic therapy of intestinal inflammation and infections. Curr Opin Gastroenterol. 2005 Jan;21(1):44-50. Review.

Sakamoto N, Kono S, Wakai K, Fukuda Y, Satomi M, Shimoyama T, Inaba Y, Miyake Y, Sasaki S, Okamoto K, Kobashi G, Washio M, Yokoyama T, Date C, Tanaka H; Epidemiology Group of the Research Committee on Inflammatory Bowel Disease in Japan. Dietary risk factors for inflammatory bowel disease: a multicenter case-control study in Japan. Inflamm Bowel Dis. 2005 Feb;11(2):154-63.

Homann N, Klarmann U, Fellermann K, Bruning A, Klingenberg-Noftz R, Witthoft T, Stange EF, Ludwig D. Mesenteric pulsatility index analysis predicts response to azathioprine in patients with Crohn's disease.
Inflamm Bowel Dis. 2005 Feb;11(2):126-32.

Regueiro M, Kip KE, Cheung O, Hegazi RA, Plevy S. Cigarette smoking and age at diagnosis of inflammatory bowel disease. Inflamm Bowel Dis. 2005 Jan;11(1):42-7.

Higgins PD, Schwartz M, Mapili J, Zimmermann EM. Is endoscopy necessary for the measurement of disease activity in ulcerative colitis? Am J Gastroenterol. 2005 Feb;100(2):355-61.

Kane S, Lemieux N. The role of breastfeeding in postpartum disease activity in women with inflammatory bowel disease. Am J Gastroenterol. 2005 Jan;100(1):102-5.

Gurel S, Kiyici M. Ulcerative colitis activity index: a useful prognostic factor for predicting ulcerative colitis outcome. J Int Med Res. 2005 Jan-Feb;33(1):103-10.

Ajaj WM, Lauenstein TC, Pelster G, Gerken G, Ruehm SG, Debatin JF, Goehde SC. Magnetic resonance colonography for the detection of inflammatory diseases of the large bowel: quantifying the inflammatory activity.
Gut. 2005 Feb;54(2):257-63.

Schreyer AG, Rath HC, Kikinis R, Volk M, Scholmerich J, Feuerbach S, Rogler G, Seitz J, Herfarth H. Comparison of magnetic resonance imaging colonography with conventional colonoscopy for the assessment of intestinal inflammation in patients with inflammatory bowel disease: a feasibility study. Gut. 2005 Feb;54(2):250-6.

Buning C, Molnar T, Nagy F, Lonovics J, Weltrich R, Bochow B, Genschel J, Schmidt H, Lochs H. NOD2/CARD15 gene polymorphism in patients with inflammatory bowel disease: is Hungary different? World J Gastroenterol. 2005 Jan 21;11(3):407-11.

Kohno H, Mizuno M, Nasu J, Makidono C, Hiraoka S, Inaba T, Yamamoto K, Okada H, Fujita T, Shiratori Y.  

Stool decay-accelerating factor as a marker for monitoring the disease activity during leukocyte apheresis therapy in patients with refractory ulcerative colitis. J Gastroenterol Hepatol. 2005 Jan;20(1):73-8.